Capital Markets Day: Commercial Execution and Innovation in Obesity Care

18 Commercial execution and innovation Obesity care Novo Nordisk is developing a portfolio of superior treatment solutions for obesity Building a competitive portfolio Bariatric surgery levels Pipeline overview Pipeline products 2022 2023 2024 2025 +20% CagriSema 15-20% ONCE-WEEKLY wegovy Oral Amycretin SELECT CVOT Phase 3 Semaglutide 2.4 mg Oral semaglutide Oral semaglutide 50 mg Phase 3 semaglutide injection 2.4 mg (50mg) CagriSema Obesity Saxenda® 5-10% PYY 1875 liraglutide injection LA-GDF15 0-5% Lifestyle modification Oral Amycretin CagriSema; Cagrilintide in combination with semaglutide Phase 2 Phase 1 Phase 1 Phase 3 Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY

View entire presentation